[go: up one dir, main page]

MX2024008109A - Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano. - Google Patents

Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano.

Info

Publication number
MX2024008109A
MX2024008109A MX2024008109A MX2024008109A MX2024008109A MX 2024008109 A MX2024008109 A MX 2024008109A MX 2024008109 A MX2024008109 A MX 2024008109A MX 2024008109 A MX2024008109 A MX 2024008109A MX 2024008109 A MX2024008109 A MX 2024008109A
Authority
MX
Mexico
Prior art keywords
extracellular domain
kits
compositions
methods
antibody
Prior art date
Application number
MX2024008109A
Other languages
English (en)
Inventor
Peter Schwind
John A Hall
Jody Berry
Vincenzo Favaloro
Elizabeth A Booth
Matteo Binda
Original Assignee
Grifols Diagnostic Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Diagnostic Solutions Inc filed Critical Grifols Diagnostic Solutions Inc
Publication of MX2024008109A publication Critical patent/MX2024008109A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición que se une a un anticuerpo anti-CD38 que incluye una secuencia especifica de una forma recombinante soluble de un dominio extracelular de CD38 y/o un fragmento del mismo que interfiere con la actividad de unión de un anticuerpo anti-CD38. La composición puede ser incluida en un kit para ensayos de diagnóstico e investigación mediante biomonitorización. La composición puede ser utilizada para neutralizar un anticuerpo anti-CD38 en una muestra y/o para seleccionar una unidad de eritrocitos adecuada para un paciente tratado con anticuerpos anti- CD38.
MX2024008109A 2017-08-10 2020-02-06 Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano. MX2024008109A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762543788P 2017-08-10 2017-08-10

Publications (1)

Publication Number Publication Date
MX2024008109A true MX2024008109A (es) 2024-07-19

Family

ID=62846219

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020001489A MX2020001489A (es) 2017-08-10 2018-06-01 Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano.
MX2024008109A MX2024008109A (es) 2017-08-10 2020-02-06 Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano.
MX2024005669A MX2024005669A (es) 2017-08-10 2020-02-06 Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020001489A MX2020001489A (es) 2017-08-10 2018-06-01 Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024005669A MX2024005669A (es) 2017-08-10 2020-02-06 Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano.

Country Status (18)

Country Link
US (3) US11708418B2 (es)
EP (3) EP3464343B1 (es)
JP (3) JP6833851B2 (es)
KR (2) KR20240015159A (es)
CN (2) CN109790210B (es)
AR (1) AR112357A1 (es)
AU (2) AU2018313028B2 (es)
BR (1) BR112020002636A2 (es)
CA (1) CA3070789A1 (es)
EA (1) EA202090265A1 (es)
ES (2) ES2973864T3 (es)
HU (1) HUE065510T2 (es)
MX (3) MX2020001489A (es)
PL (1) PL3587445T3 (es)
PT (1) PT3587445T (es)
TW (1) TW201910349A (es)
UY (1) UY37757A (es)
WO (1) WO2019030581A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3070789A1 (en) * 2017-08-10 2019-02-14 Grifols Diagnostic Solutions Inc. Compositions, methods and/or kits comprising a recombinant human cd38-extracellular domain
TW202000692A (zh) * 2018-02-20 2020-01-01 美商格里佛診斷方法股份有限公司 包含GpIbα的多肽和組合物、編碼該多肽的核酸及包含該多肽或該核酸的細胞
CN112048019B (zh) * 2019-06-06 2023-05-09 鲁南制药集团股份有限公司 抗人cd47单克隆抗体
JP2023541254A (ja) * 2020-09-10 2023-09-29 キャシ ファーマシューティカルズ インコーポレイテッド 血液スクリーニング方法
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN114917413B (zh) * 2022-06-14 2023-04-28 健诺维(成都)生物科技有限公司 一种负载重组多肽的羊膜及其制备方法
WO2024172419A1 (ko) * 2023-02-16 2024-08-22 주식회사 디엔티 Cd38 또는 이의 단편을 포함하는 자가면역질환 치료용 조성물
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6506551B1 (en) * 1999-10-08 2003-01-14 North Shore - Long Island Jewish Research Institute CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia
AU2001273121A1 (en) * 2000-06-30 2002-01-14 Pharmacia And Upjohn Company Recombinant staphylococcus aureus peptide deformylase
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
SI2511297T1 (sl) * 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
US9040050B2 (en) * 2006-09-26 2015-05-26 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN107011445B (zh) * 2007-06-01 2021-06-29 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
JP2011500005A (ja) * 2007-10-11 2011-01-06 ユニバーシティー ヘルス ネットワーク ヒト造血幹細胞の生着を増加させるためのＳＩＲＰα−ＣＤ４７相互作用の調節およびそのための化合物
CA2738545A1 (en) 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
WO2010037837A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
WO2010083253A2 (en) * 2009-01-14 2010-07-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
RS61136B1 (sr) * 2010-02-19 2020-12-31 Xencor Inc Novi ctla4-ig imunoadhezini
US20130029358A1 (en) * 2010-04-01 2013-01-31 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
EP2530089A1 (en) * 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
MX360772B (es) * 2012-02-06 2018-11-15 Inhibrx Inc Anticuerpos cd47 y metodos de uso de los mismos.
KR102213694B1 (ko) * 2012-04-27 2021-02-09 노보 노르디스크 에이/에스 사람 cd30 리간드 항원 결합 단백질
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9447193B2 (en) * 2013-03-24 2016-09-20 Development Center For Biotechnology Methods for suppressing cancer by inhibition of TMCC3
US9599606B2 (en) * 2014-06-10 2017-03-21 The Board Of Regents Of The University Of Texas System ADP-ribose detection reagents
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
KR20170081699A (ko) * 2014-11-18 2017-07-12 얀센 파마슈티카 엔.브이. Cd47 항체, 방법 및 용도
EP3263599A4 (en) * 2015-02-16 2018-12-19 Pharma Foods International Co., Ltd. Anti-cancer agent and antimetastatic agent using fstl1, and concomitant drug for same
US9944679B2 (en) * 2015-03-16 2018-04-17 The Catholic University Of America Authentic trimeric HIV-1 envelope glycoproteins comprising a long linker and tag
ES2768784T3 (es) * 2015-03-23 2020-06-23 Bayer Pharma AG Anticuerpos anti-CEACAM6 y usos de los mismos
ES2846175T3 (es) * 2015-09-08 2021-07-28 Eisai R&D Man Co Ltd Anticuerpo anti-EphA4
JP2019503167A (ja) * 2015-11-10 2019-02-07 ユニバーシティ・メディカル・センター・ハンブルク−エッペンドルフＵｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Ｈａｍｂｕｒｇ − Ｅｐｐｅｎｄｏｒｆ Ｃｄ３８に対する抗原結合性ポリペプチド
CA3070789A1 (en) * 2017-08-10 2019-02-14 Grifols Diagnostic Solutions Inc. Compositions, methods and/or kits comprising a recombinant human cd38-extracellular domain

Also Published As

Publication number Publication date
CN109790210A (zh) 2019-05-21
ES2973864T3 (es) 2024-06-24
EP3464343B1 (en) 2022-03-23
PT3587445T (pt) 2024-03-14
US20240132616A1 (en) 2024-04-25
KR20240015159A (ko) 2024-02-02
HUE065510T2 (hu) 2024-05-28
KR20200035194A (ko) 2020-04-02
EP3587445B1 (en) 2023-12-13
JP2019527533A (ja) 2019-10-03
MX2020001489A (es) 2020-03-20
US20240092929A1 (en) 2024-03-21
AU2018313028A1 (en) 2020-02-20
EP4296680A2 (en) 2023-12-27
JP6833851B2 (ja) 2021-02-24
AU2018313028B2 (en) 2023-05-25
EP3464343A1 (en) 2019-04-10
JP2023041802A (ja) 2023-03-24
CA3070789A1 (en) 2019-02-14
CN109790210B (zh) 2024-03-26
WO2019030581A1 (en) 2019-02-14
AU2023204121A1 (en) 2023-07-20
EP4296680A3 (en) 2024-03-20
JP7289328B2 (ja) 2023-06-09
BR112020002636A2 (pt) 2020-07-28
TW201910349A (zh) 2019-03-16
EA202090265A1 (ru) 2020-06-05
US11708418B2 (en) 2023-07-25
KR102631281B1 (ko) 2024-01-30
PL3587445T3 (pl) 2024-04-29
UY37757A (es) 2018-11-30
JP2021088567A (ja) 2021-06-10
ES2911243T3 (es) 2022-05-18
MX2024005669A (es) 2024-05-30
US20210198376A1 (en) 2021-07-01
US20240228651A9 (en) 2024-07-11
AR112357A1 (es) 2019-10-23
EP3587445A1 (en) 2020-01-01
CN117820498A (zh) 2024-04-05

Similar Documents

Publication Publication Date Title
MX2024008109A (es) Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano.
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
CO2019012118A2 (es) Anticuerpo anti-pd-l1 y uso del mismo
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
CO2018000882A2 (es) Constructos de anticuerpo para flt3 y cd3
DOP2016000282A (es) Anticuerpos humanizados contra la molécula de adhesión celular relacionada al antígeno carcinoembriónico 1 (ceacam1)
BR112018002824A2 (pt) anticorpo, polinucleotídeo, vetor, célula, métodos para expressar o anticorpo, para tratar uma condição associada com pd-1 e para tratar uma condição em um sujeito, kit, composição farmacêutica e uso do anticorpo
EA201890383A8 (ru) Конструкции биспецифических антител, связывающиеся с мезотелином и кд3 (cd3)
EA201890382A1 (ru) Конструкции антител для cd70 и cd3
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
ECSP21010450A (es) Anticuerpos anti–sortilina y métodos para su uso
ECSP11011297A (es) Proteinas ligadoras il-17
MX2018009738A (es) Anticuerpos monoclonales de proteína ns1 anti-virus del dengue.
EA201690731A1 (ru) Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах
EA201690992A1 (ru) Антитела, специфичные к fcrn
JOP20200343A1 (ar) بروتين ربط مولد ضد مضاد لـ steap1
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
PH12021552536A1 (en) Methods for treatment of subjects with psoriatic arthritis
CO2024000024A2 (es) Moléculas de unión a gpc3
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
MX2020005562A (es) Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1.
AR110680A1 (es) Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x
MX2021001544A (es) Uso de lc-ms/ms para cuantificar biomarcadores proteicos.
BR112018075901A2 (pt) anticorpo humanizado ou fragmento de ligação a anticorpo, uso deste, complexo in vitro, opcionalmente isolado, e método in vitro
EA202092208A1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОТНОМ pH